This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 30, 2025 to its short form base shelf prospectus dated May 15, 2025. MIAMI, June 02, 2025 (GLOBE NEWSWIRE) -- Digi Power X Inc. (“Digi Power X” or the “Company”) (Nasdaq: DGXX / TSXV: DGX), an innovative energy infrastructure company that develops cutting-edge data centers, is pleased to provide unaudited comparative Bitcoin (“BTC”) production results for the month ended May 31, 2025, ...

Dosing cohort 3 of Phase 1 trial of CTIM-76, a Claudin 6 x CD3 T cell engager Expect to share initial data in the first half of 2026 PHILADELPHIA, June 02, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors, announced today that it is presenting a Trial in Progress poster for the Phase 1 clinical trial evaluating CTIM-76 in ovarian, endometrial, and tes ...

Company Overview - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering, creating, testing, and delivering transformative medicines for genetic diseases [3] - Founded in 2015, the company has a pipeline that includes programs from early science to advanced clinical trials [3] - The team consists of experienced drug discoverers, developers, and innovators dedicated to applying advances in genetic medicine [3] Upcoming Event - Members of BridgeBio's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on June 9 at 8:40 am ET [1] - A live webcast of the presentation will be available on the company's website, with a replay accessible for 30 days post-event [2]

Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ studies in metastatic breast cancer (MBC)Median Overall Survival of 17.3 months in Phase 2 study patients treated with Phase 3 formulation (since 2022) is superior to outcomes reported for comparable patients in the literatureMeaningful Clinical Benefit observed in all MBC subtypes, including HER2+, HR+/HER2-, and triple-negative breast cancer (TNBC)Overall survival and clinical benefit data repo ...

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- Amerigo Resources Ltd. (TSX: ARG; ARREF:OTC) (“Amerigo” or the “Company”) is pleased to announce the appointment of Ignacio Cruz to the Company’s board of directors. Ignacio Cruz is a Civil Engineer with over forty years of experience in leading positions in the Chilean mining, energy, and civil society sectors. Most recently, Mr. Cruz was Executive Chair of TECHO International, Latin America’s largest NGO with operations in 19 countries. Before ...

TORONTO, June 02, 2025 (GLOBE NEWSWIRE) -- Emerita Resources Corp. (TSX-V: EMO; OTCQB: EMOTF; FSE: LLJA) (the “Company” or “Emerita”) provides comments with respect to the announcement made on May 30, 2025 by the Minister of Energy and Mines of Andalucia, Mr. Jorge Paradela, that the Junta de Andalucia, through his ministry, has granted the exploitation license to Minera Los Frailes (“MLF”) to develop the Aznalcollar project. Spanish independent legal counsel of Emerita has reassured the Company that this a ...

VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year. For the three months ended March 31, 2025 the Company realized revenues of $434,061 with a gross profit of $346,297. The Company recorded a comprehensive loss of $77,300 with a net increase in cash of $137,068. Plan the Work – Work the Plan The Company is cu ...

Press Release dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025 dsm-firmenich, innovators in nutrition, health, and beauty, today announces the successful completion of the sale of its stake in the Feed Enzymes Alliance to its partner Novonesis, a global leader in biosolutions, for €1.5 billion. The sale agreement was announced on February 11, 2025. dsm-firmenich received approximately €1.4 billi ...

Group 1 - Dow has signed a sale and purchase agreement to sell its 50% interest in DowAksa Advanced Composites Holdings BV to Aksa Akrilik Kimya Sanayii A.Ş. for expected proceeds of $125 million, reflecting an enterprise value of approximately 10x the estimated 2025 operating EBITDA [1][2] - The decision to exit the joint venture aligns with Dow's strategy to focus on core, high-value downstream businesses, and the proceeds will support the company's balanced capital allocation approach [2][4] - The sale is anticipated to close in the third quarter of 2025, pending customary regulatory approvals and other closing conditions [2] Group 2 - Dow is a leading materials science company with a focus on high-growth markets such as packaging, infrastructure, mobility, and consumer applications, delivering sales of approximately $43 billion in 2024 [3] - The company operates manufacturing sites in 30 countries and employs around 36,000 people, emphasizing its commitment to sustainability and profitable growth [3]

~ Alignment with FDA continues to support Accelerated Approval pathway ~ ~ BLA submission planned for first quarter of 2026 ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, June 02, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today provided a regulatory update on AMT-130, its investigational gene therapy for the treatment of Huntington’s disease. Following recent Typ ...